著者らは、このプロトコルの開発で助けジェンキンスラボのアンドレ漢とローレンス·イェン技術上の支援のため、メンバーに感謝したいと思います。

1。リンパ組織からの細胞の単離<ol><li>の小さな正方形を含む60mmの培養皿に、氷冷cEHAA（EHAA +10％FBS、ペニシリン/ストレプトマイシン、ゲンタマイシン、2mM L-グルタミン、55 mM 2 - メルカプトエタノール）または他の同等のT細胞培地1mlを追加氷の上に100μmのナイロンメッシュと場所。 </li><li>マウスを安楽死させる。 </li><li>脾臓、できるだけ多くの簡単にアクセスできるリンパ節を切除する。これらは少なくとも鼠径部、腋窩、上腕、頸部、および腸間膜リンパ節を含める必要があります。培養皿にナイロンメッシュの上に置きます。 </li><li>ナイロンメッシュ上のリンパ組織はリンパ球を解放するために、閉じた1.5 mlのマイクロチューブのフラットトップを使って、 優しくマッシュ。懸濁液中に細胞を動作するように上下cEHAAとピペットの別の1ミリリットルを追加します。 15 mlのポリプロピレン製遠心分離管の上に配置されたナイロンメッシュの別の部分を介して細胞を移す。氷冷cEHAA、POの別の1ミリリットルと皿とメッシュをすすぐ同じチューブにボリュームをoling。 4ミリリットルの最終細胞懸濁液の容積を達成するために繰り返します。 </li><li> 15ミリリットルの最終容量に冷たいソーター酸緩衝液（PBS + 2％FBS、0.05％アジ化ナトリウム）を追加し、300×gで5分間遠心分離管を、4℃ </li><li>慎重に液体が滴がチューブの両側に残っていないことを確認し、上清を吸引除去する。約2倍のペレット自体のそれに等しい最終容量へのFcブロック（ソーターバッファ+ 2.4G2抗体）で細胞ペレットを再懸濁します。例えば、ナイーブマウスの脾臓およびリンパ節は通常、約100μlの細胞ペレットを生成します。この場合は、200μlにボリュームを持って来るためのFcブロックの100μlを添加する。細胞凝集度が大きいが発生した場合は、ピペットチップを用いて、この時点で細胞塊を除去します。 </li></ol> 2。四量体染色<ol><li> 10 NM（または経験的に最適化された濃度）の最終濃度にPEまたはAPC標識pMHC複合テトラマーを追加します。 </li><li>ミックスとインキュベーション室温で1時間TE（または経験的に最適化された時間と温度）。 </li><li> 15ミリリットルの容積に冷たいソーター·バッファを追加し、300×gで、4℃で5分間、チューブを遠心氷の上または°C今から4でサンプルを保管してください。 </li><li>慎重に液体が滴がチューブの両側に残っていないことを確認し、上清を吸引除去する。 200μlの最終容量にソーター·バッファ内の細胞ペレットを再懸濁します。二量体の濃縮​​は、150μlの最終容量に再懸濁します。 </li></ol> 3。磁気濃縮<ol><li>ミルテニー抗PEまたは抗APCマイクロビーズの50μlを添加する。二量体の濃縮​​のために、両方の50μlを添加する。 </li><li> 4で混ぜ合わせ、20分間インキュベート℃、 </li><li> 15ミリリットルの容積に冷たいソーター·バッファを追加し、300×gで、4℃で5分間、チューブを遠心</li><li>待っている間、またはMidiMACS QuadroMACS磁石にミルテニーLSの磁気カラムを設定します。上の開いている15mlのポリプロピレン遠心管を置き列の真下ラック。 </li><li>それは15 mlのチューブに排出できるように、列の先頭にソーター緩衝液3mlを加える。 </li><li>列の上に100μmのナイロンメッシュ正方形を置きます。 </li><li>細胞が回転し終わったら、慎重に上清を吸引し、ソーター緩衝液3mlでペレットを再懸濁します。 </li><li>カラムの上にナイロンメッシュを介して細胞懸濁液を移す。 </li><li>細胞懸濁液が完全にカラムに排水されている場合、プロセス内でメッシュをすすぎ、ソータバッファの別の3mlでオリジナルのチューブを洗浄し、カラムにナイロンメッシュを介してバッファを転送します。ナイロンメッシュを破棄します。 </li><li>バッファが完全にカラムに排水している場合、その列にソーター·バッファの別の3ミリリットルを追加します。 </li><li> 3×3 mlの洗浄の合計に対して、ステップ10を繰り返します。 </li><li>新しい15 mlのポリプロピレン製遠心管を介して磁石と場所からカラムを取り外します。 </li><li> tにソーター緩衝液5mlを追加彼列。 </li><li>すぐに列の上部にプランジャーを挿入し、一つの連続した​​動きで、チューブにカラムOUTバッファを強制的に、プランジャーのすべての方法を下に押します。 </li><li> 300×gで5分間溶出結合画分およびフロースルー非結合画分、4℃を含むチューブを遠心</li><li>慎重に液体が滴がチューブの両側に残っていないことを確認しながら、結合画分から上清を吸引除去する。正確に95μlの最終容量にソーター·バッファ内の細胞ペレットを再懸濁します。 2ミリリットルの最終容量に非結合画分を吸引除去し、再懸濁します。 </li></ol> 4。フローサイトメトリー<ol><li>各画分については、5μlを削除し、5ミリリットルのFACS管で計数ビーズを200μl（ソーター·バッファ内の20万個/ mlの濃度に調整）に追加します。 4で取っておく°後の分析のためのC。時間を節約するために、ビーズは、実験開始前にラベルしたチューブにあらかじめ等分することができます。 </li><li>午前の準備ASTERは、セル（ 表1）の表面マーカーを染色する抗体のミックス。時間を節約するために、これは実験の開始前に行うことができます。 </li><li>結合分画は、チューブ内の細胞の約90μlに直接抗体カクテルの用量を追加します。非結合画分の分析が必要な場合は、5ミリリットルのFACSチューブに細胞の90μlを転送し、抗体カクテルの用量を追加します。 </li><li>フローサイトメーター用の単一色補正のコントロールパネルを設定します。使用する各蛍光色素の場合は、対応する蛍光色素に結合した抗CD4抗体の1μlを5ミリリットルのFACSチューブ内に残った非結合分画細胞の50μlを混合します。同様に染色されていないコントロールを設定することを忘れないでください。 </li><li>ボルテックスし、4℃で30分間、すべてのサンプルをインキュベート℃に</li><li> 300×gで5分間、4℃で各チューブと遠心分離機にソーター緩衝液5mlを追加</li><li>結合画分については、慎重に上清を吸引し、ソーターbufの200μlの細胞を再懸濁FER。 1.2ミリリットルのFACSマイクロチューブに細胞を移します。同じマイクロチューブにソーター·バッファーおよびプールの別の200μlで管を洗浄します。細胞塊が明らかである場合には、50μmのフィルターを介して細胞を渡す。 </li><li>非結合画分と補償コントロール、またはデカントで上澄みを再懸濁し、2mlのソーターバッファを吸引するための。 </li><li>単一色補正コントロールを使用して、フローサイトメーターを設定します。記録する追加パラメータとして、側方散乱幅（SSC-W）を選択します。 </li><li> 図1および図2に示すように、CD4 +またはCD8 + T細胞を同定するために連続したインクルージョンゲートのシーケンスを使用して染色したサンプルを分析します。結合画分については、最大2,000,000の合計の最大イベントにできるだけ多くの細胞を収集しています。非結合分画、1,000,000合計イベントを収集します。買収レートを1秒あたりのイベントで、または3000以下に保つ。 </li><li>同じマシンの設定を使用して、数えるビーズサンプルを分析する。万合計イベントを収集します&lt;/ LI&gt; <li> FCSのファイルなど、すべてのデータを保存します。 </li></ol> 5。データ解析<ol><li> FlowJoソフトウェアを使用してカウントビーズサンプル用のFCSデータファイルを分析します。前方にプロットFITCによって散乱および（ 図1および図2を参照）をカウントするビーズをaroungゲートを設定します。各試料で検出されたビーズをカウントの合計数を決定する。採取した細胞イベントの数を決定するために収集されたイベントの合計数から減算します。 </li><li>ボックス1で概説方程式を用いて、各サンプル中のすべてのセルの総数を計算します。 </li><li>ステンドバインドおよび非バインド分数サンプル用のFCSデータファイルを分析します。リンパ+サイド散布幅LO、ダンプ、CD3 +、CD4 +またはCD8 +、テトラマー、図1および図2に示すように、各試料中の+ T細胞。を識別するために、連続的なインクルージョンゲートのシーケンスを設定</li><li> CD4を定義するために使用される包接ゲートの各々の周波数によって、サンプル中の細胞の総数を掛け+テトラマー+またはCD8 +テトラマー+細胞エピトープ特異的T細胞（ボックス1）の合計数を計算する。 </li></ol>

<ol>
	<li>Knutson, K. L., dela Rosa, C., Disis, M. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Laboratory+analysis+of+T-cell+immunity.">Laboratory analysis of T-cell immunity.</a> Front Biosci. 11, 1932-1944 (2006).</li><li>Kearney, E. R., Pape, K. A., Loh, D. Y., Jenkins, M. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Visualization+of+peptide-specific+T+cell+immunity+and+peripheral+tolerance+induction+in+vivo.">Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo.</a> Immunity. 1, 327-339 (1994).</li><li>Moon, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tracking+epitope-specific+T+cells.">Tracking epitope-specific T cells.</a> Nat Protoc. 4, 565-581 (2009).</li><li>Hataye, J., Moon, J. J., Khoruts, A., Reilly, C., Jenkins, M. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Naive+and+memory+CD4++T+cell+survival+controlled+by+clonal+abundance.">Naive and memory CD4+ T cell survival controlled by clonal abundance.</a> Science. 312, 114-116 (2006).</li><li>Marzo, A. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Initial+T+cell+frequency+dictates+memory+CD8++T+cell+lineage+commitment.">Initial T cell frequency dictates memory CD8+ T cell lineage commitment.</a> Nat Immunol. 6, 793-799 (2005).</li><li>Davis, M. M., Altman, J. D., Newell, E. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Interrogating+the+repertoire:+broadening+the+scope+of+peptide-MHC+multimer+analysis.">Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis.</a> Nature reviews. Immunology. 11, 551-558 (2011).</li><li>Moon, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Naive+CD4(+)+T+cell+frequency+varies+for+different+epitopes+and+predicts+repertoire+diversity+and+response+magnitude.">Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude.</a> Immunity. 27, 203-213 (2007).</li><li>Seah, S. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+linear+range+for+accurately+quantifying+antigen-specific+T-cell+frequencies+by+tetramer+staining+during+natural+immune+responses.">The linear range for accurately quantifying antigen-specific T-cell frequencies by tetramer staining during natural immune responses.</a> European Journal of Immunology. 41, 1499-1500 (2011).</li><li>Obar, J. J., Khanna, K. M., Lefrancois, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Endogenous+naive+CD8++T+cell+precursor+frequency+regulates+primary+and+memory+responses+to+infection.">Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection.</a> Immunity. 28, 859-869 (2008).</li><li>Daniels, M. A., Jameson, S. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Critical+role+for+CD8+in+T+cell+receptor+binding+and+activation+by+peptide/major+histocompatibility+complex+multimers.">Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers.</a> J Exp Med. 191, 335-346 (2000).</li><li>Pittet, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Alpha+3+domain+mutants+of+peptide/MHC+class+I+multimers+allow+the+selective+isolation+of+high+avidity+tumor-reactive+CD8+T+cells.">Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells.</a> Journal of Immunology. 171, 1844-1849 (2003).</li><li>Choi, E. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High+avidity+antigen-specific+CTL+identified+by+CD8-independent+tetramer+staining.">High avidity antigen-specific CTL identified by CD8-independent tetramer staining.</a> Journal of Immunology. 171, 5116-5123 (2003).</li><li>Chu, H. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Positive+selection+optimizes+the+number+and+function+of+MHCII-restricted+CD4++T+cell+clones+in+the+naive+polyclonal+repertoire.">Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire.</a> Proc Natl Acad Sci U S A. 106, 11241-11245 (2009).</li><li>Chu, H. H., Moon, J. J., Kruse, A. C., Pepper, M., Jenkins, M. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Negative+Selection+and+Peptide+Chemistry+Determine+the+Size+of+Naive+Foreign+Peptide-MHC+Class+II-Specific+CD4++T+Cell+Populations.">Negative Selection and Peptide Chemistry Determine the Size of Naive Foreign Peptide-MHC Class II-Specific CD4+ T Cell Populations.</a> J Immunol. 185, 4705-4713 (2010).</li><li>Legoux, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Impact+of+TCR+reactivity+and+HLA+phenotype+on+naive+CD8+T+cell+frequency+in+humans.">Impact of TCR reactivity and HLA phenotype on naive CD8 T cell frequency in humans.</a> J Immunol. 184, 6731-6738 (2010).</li><li>Alanio, C., Lemaitre, F., Law, H. K., Hasan, M., Albert, M. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enumeration+of+human+antigen-specific+naive+CD8++T+cells+reveals+conserved+precursor+frequencies.">Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies.</a> Blood. 115, 3718-3725 (2010).</li><li>Kwok, W. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Frequency+of+Epitope-Specific+Naive+CD4++T+Cells+Correlates+with+Immunodominance+in+the+Human+Memory+Repertoire.">Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoire.</a> Journal of Immunology. 188, 2537-2544 (2012).</li><li>Jenkins, M. K., Chu, H. H., McLachlan, J. B., Moon, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=On+the+composition+of+the+preimmune+repertoire+of+T+cells+specific+for+Peptide-major+histocompatibility+complex+ligands.">On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands.</a> Annu Rev Immunol. 28, 275-294 (2010).</li><li>Matechak, E. O., Killeen, N., Hedrick, S. M., Fowlkes, B. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MHC+class+II-specific+T+cells+can+develop+in+the+CD8+lineage+when+CD4+is+absent.">MHC class II-specific T cells can develop in the CD8 lineage when CD4 is absent.</a> Immunity. 4, 337-347 (1996).</li><li>Burchill, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Linked+T+cell+receptor+and+cytokine+signaling+govern+the+development+of+the+regulatory+T+cell+repertoire.">Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.</a> Immunity. 28, 112-121 (2008).</li><li>Pepper, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Different+routes+of+bacterial+infection+induce+long-lived+TH1+memory+cells+and+short-lived+TH17+cells.">Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells.</a> Nature Immunology. 11, 83-89 (2010).</li></ol>

特別な利害関係は宣言されません。

このプロトコルによって提示pMHC複合テトラマー基づく細胞濃縮法は、内因性のT細胞レパートリーからエピトープ特異的T細胞を研究するための強力なツールです。 pMHC複合テトラマーの使用は、同族のpMHC複合リガンドと結合するTCRの能力に直接基づくエピトープ特異的T細胞の検出を可能にします。濃縮は、抗原特異的T細胞の非常にまれな集団が彼らの遺伝子構造または前駆周波数の任意の?...

<table border="1"&gt;<tbody&gt;<tr&gt;<td<strong&gt;試薬</strong</td&gt;<td<strong&gt;ベンダー</strong</td&gt;<td<strong&gt;カタログ番号</strong</td&gt;</tr&gt;<tr&gt;<td&gt; PEまたはAPCの共役pMHC複合テトラマー（またはマルチマー）</td&gt;<td&gt; NIHのテトラマーコアから得られた、研究者によって作られた、または商業的供給源から購入</td&gt;<td</td&gt;</tr&gt;<tr&gt;<td&gt;アンチPE結合磁性マイクロビーズ</td&gt;<td&gt;ミルテニー</td&gt;<td&gt; 130-048-801</td&gt;</tr&gt;<tr&gt;<td&gt;アンチAPC共役磁性マイクロビーズ</td&gt;<td&gt;ミルテニー</td&gt;<td&gt; 130-090-855</td&gt;</tr&gt;<tr&gt;<td&gt; LS磁気列</td&gt;<td&gt;ミルテニー</td&gt;<td&gt; 130-042-401</td&gt;</tr&gt;<tr&gt;<td&gt; MidiMACSまたはQuadroMACS磁石</td&gt;<td&gt;ミルテニー</td&gt;<td&gt; 130-042-302または130-090-976</td&gt;</tr&gt;<tr&gt;<td&gt;細胞計数ビーズ</td&gt;<td&gt;ライフテクノロジーズ</td&gt;<td&gt; PCB-100</td&gt;</tr&gt;</tbody&gt;</table

peptide:mhc tetramer-based enrichment of epitope-specific t cells

in vivo実験モデルでと適応免疫を勉強研究者のための基本的な必要性は、それらのT細胞抗原受容体（TCR）の特異性に基づいてT細胞を識別する能力である。 T細胞のバルク集団が特定の抗原およびエピトープ特異的T細胞をin vitro で刺激されている多くの間接的な方法が利用可能です、増殖、サイトカイン産生や活性化マーカー1の発現などの機能的応答の測定によって識別されます。しかし、これらの方法では、唯一の多くの可能な機能の一つを示すエピトープ特異的T細胞を同定し、そして、彼らは素朴な前駆周波数でエピトープ特異的T細胞を検出するのに十分な小文字は区別されません。人気のある選択肢は、TCRトランスジェニック養子移入モデルであるTCRトランスジェニックマウス由来モノクローナルT細胞はEASIできるエピトープ特異的T細胞の大前駆体細胞集団を作成するために組織適合ホストに播種するLyはコンジェニックマーカー抗体2,3の使用で追跡。パワフルながら、この方法では、4,5の単一エピトープに対して特異性を有するT細胞の非生理的な周波数に関連付けられている実験的な成果物に苦しんでいる。また、本システムは、ポリクローナル集団内のエピトープ特異的T細胞クローンの機能的な異質性を調査するために使用することはできません。 MHC（pMHC複合）錯体：適応免疫を研究するための理想的な方法は、単にその同族ペプチドに結合することにより、TCRの特異性を区別する方法を用いて内因性のT細胞レパートリーからのエピトープ特異的T細胞の直接検出を関与させるべきである。 pMHC複合テトラマーおよびフローサイトメトリーの使用は、この6を達成しますが、のみ、次の抗原誘発クローン増殖を発見したエピトープ特異的T細胞の高頻度の個体群の検出に限定されています。このプロトコルでは、pMHC複合テトラマーの使用を調整する方法を説明し、マグネチック細胞濃縮技術は、マウスリンパ組織3,7から超低周波エピトープ特異的T細胞の検出を可能にします。この手法では、1は、包括的に免疫応答の全ての段階で、マウスにおける内因性T細胞の全体のエピトープ特異的集団を追跡することができます。

図2は、以前に関連するペプチド+ CFAで免疫したマウスについての代表的なデータを示しながら、 図1は 、ナイーブマウスからpMHCIIテトラマー濃縮脾臓及びリンパ節試料の代表的なフローサイトメトリープロットを描いている。シリアル·ゲーティングは、CD4の分析+ T細胞集団からの自家蛍光およびその他の不要なイベントを削除します。 CD8 + T細胞集団?...

Watch this Scientific Journal Video about Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells at JoVE.com

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

エピトープ特異的T細胞の低周波の集団を区別し、フローサイトメトリーによって、それらを分析するためのMHCテトラマーと磁性マイクロビーズ：このプロトコルは、ペプチドの使用について説明します。この方法は、から対象の内因性T細胞集団の直接調査を可能に<em生体内で&gt;</em&gt;実験システム。

ペプチドエピトープ特異的T細胞のMHCテトラマーベースの濃縮

A  basic necessity for researchers studying adaptive immunity with in vivo experimental models is an  ability to identify T cells based on their T cell ...

peptidemhc-tetramer-based-enrichment-of-epitope-specific-t-cells

Research

JoVE Journal

Immunology and Infection

17.8K ビュー.  Massachusetts General Hospital and Harvard Medical School. エピトープ特異的T細胞の低周波の集団を区別し、フローサイトメトリーによって、それらを分析するためのMHCテトラマーと磁性マイクロビーズ：このプロトコルは、ペプチドの使用について説明します。この方法は、から対象の内因性T細胞集団の直接調査を可能に実験システム。

ビデオ: Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Retroviral Transduction of T-cell Receptors in Mouse T-cells

T-cell receptors (TCRs) play a central role in the immune system. TCRs on T-cell surfaces can specifically recognize peptide antigens presented by antigen presenting cells (APCs)1. This recognition leads to the activation of T-cells and a series of functional outcomes (e.g. cytokine production, killing of the target cells). Understanding the functional role of TCRs is critical to harness the power of the immune system to treat a variety of immunology related diseases (e.g. cancer or autoimmunity).
It is convenient to study TCRs in mouse models, which can be accomplished in several ways. Making TCR transgenic mouse models is costly and time-consuming and currently there are only a limited number of them available2-4. Alternatively, mice with antigen-specific T-cells can be generated by bone marrow chimera. This method also takes several weeks and requires expertise5. Retroviral transduction of TCRs into in vitro activated mouse T-cells is a quick and relatively easy method to obtain T-cells of desired peptide-MHC specificity. Antigen-specific T-cells can be generated in one week and used in any downstream applications. Studying transduced T-cells also has direct application to human immunotherapy, as adoptive transfer of human T-cells transduced with antigen-specific TCRs is an emerging strategy for cancer treatment6.
Here we present a protocol to retrovirally transduce TCRs into in vitro activated mouse T-cells. Both human and mouse TCR genes can be used. Retroviruses carrying specific TCR genes are generated and used to infect mouse T-cells activated with anti-CD3 and anti-CD28 antibodies. After in vitro expansion, transduced T-cells are analyzed by flow cytometry.

We present a protocol to produce antigen-specific mouse T-cells using retroviral transduction

マウスT細胞におけるT細胞受容体のレトロウイルス導入

T-cell receptors (TCRs) play a central role in the immune system. TCRs on T-cell surfaces can specifically recognize peptide antigens presented by antigen ...

免疫・感染学

Generation of Induced Regulatory T Cells from Primary Human Na&iuml;ve and Memory T Cells

The development and maintenance of immunosuppressive CD4+ regulatory T cells (Tregs) contribute to the peripheral tolerance needed to remain in immunologic homeostasis with the vast amount of self and commensal antigens in and on the human body. Perturbations in the balance between Tregs and inflammatory conventional T cells can result in immunopathology or cancer. Although therapeutic injection of Tregs has been shown to be efficacious in murine models of colitis1 , type I diabetes2 , rheumatoid arthritis and graft versus host disease,4 several fundamental differences in human versus mouse Treg biology5 has thus far precluded clinical use. The lack of sufficient number, purity, stability and homing specificity of therapeutic Tregs necessitated a dynamic platform of human Treg development on which to optimize conditions for their ex vivo expansion6.
Here we describe a method for the differentiation of induced Tregs (iTregs) from a single human peripheral blood donor which can be broken down into four stages: isolation of peripheral blood mononuclear cells, magnetic selection of CD4+ T cells, in vitro cell culture and fluorescence activated cell sorting (FACS) of T cell subsets. Since the Treg signature transcription factor forkhead box P3 (FoxP3) is an activation-induced transcription factor in humans7 and no other unique marker exists, a combinatorial panel of markers must be used to identify T cells with suppressor activity. After six days in culture, cells in our system can be demarcated into na&iuml;ve T cells, memory T cells or iTregs based on their relative expression of CD25 and CD45RA. As memory and na&iuml;ve T cells have different reported polarization requirements and plasticities8 , pre-sorting of the initial T cell population into CD45RA+ and CD45RO+ subsets can be used to examine these discrepancies. Consistent with others, our CD25HiCD45RA- iTregs express high levels of FoxP39 , GITR and CTLA-411 and low levels of CD12712 . Following FACS of each population, resultant cells can be used in a suppressor assay which evaluates the relative ability to retard the proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labeled autologous T cells.

Generation of Induced Regulatory T Cells from Primary Human Na&amp;#239;ve and Memory T Cells

We describe a method for generating regulatory, memory and na&#239;ve T cells from a single human blood donor. Polarized Tregs can be then compared to other subsets in a variety of genetic and functional applications with genetic homogeneity, including a suppression assay also detailed here.

初代ヒトナイーブおよびメモリーT細胞から誘導した調節性T細胞の生成

The development and maintenance of immunosuppressive CD4+ regulatory T cells (Tregs) contribute to the peripheral tolerance needed to remain in ...

piggyBac Transposon System Modification of Primary Human T Cells

The piggyBac transposon system is naturally active, originally derived from the cabbage looper moth1,2. This non-viral system is plasmid based, most commonly utilizing two plasmids with one expressing the piggyBac transposase enzyme and a transposon plasmid harboring the gene(s) of interest between inverted repeat elements which are required for gene transfer activity. PiggyBac mediates gene transfer through a "cut and paste" mechanism whereby the transposase integrates the transposon segment into the genome of the target cell(s) of interest. PiggyBac has demonstrated efficient gene delivery activity in a wide variety of insect1,2, mammalian3-5, and human cells6 including primary human T cells7,8. Recently, a hyperactive piggyBac transposase was generated improving gene transfer efficiency9,10.
Human T lymphocytes are of clinical interest for adoptive immunotherapy of cancer11. Of note, the first clinical trial involving transposon modification of human T cells using the Sleeping beauty transposon system has been approved12. We have previously evaluated the utility of piggyBac as a non-viral methodology for genetic modification of human T cells. We found piggyBac to be efficient in genetic modification of human T cells with a reporter gene and a non-immunogenic inducible suicide gene7. Analysis of genomic integration sites revealed a lack of preference for integration into or near known proto-oncogenes13. We used piggyBac to gene-modify cytotoxic T lymphocytes to carry a chimeric antigen receptor directed against the tumor antigen HER2, and found that gene-modified T cells mediated targeted killing of HER2-positive tumor cells in vitro and in vivo in an orthotopic mouse model14. We have also used piggyBac to generate human T cells resistant to rapamycin, which should be useful in cancer therapies where rapamycin is utilized15.
Herein, we describe a method for using piggyBac to genetically modify primary human T cells. This includes isolation of peripheral blood mononuclear cells (PBMCs) from human blood followed by culture, gene modification, and activation of T cells. For the purpose of this report, T cells were modified with a reporter gene (eGFP) for analysis and quantification of gene expression by flow cytometry.
PiggyBac can be used to modify human T cells with a variety of genes of interest. Although we have used piggyBac to direct T cells to tumor antigens14, we have also used piggyBac to add an inducible safety switch in order to eliminate gene modified cells if needed7. The large cargo capacity of piggyBac has also enabled gene transfer of a large rapamycin resistant mTOR molecule (15 kb)15. Therefore, we present a non-viral methodology for stable gene-modification of primary human T cells for a wide variety of purposes.

piggyBac Transposon System Modification of Primary Human T Cells

We describe a method to genetically modify primary human T cells with a transgene using the non-viral piggyBac transposon system. T cells modified to using the piggyBac transposon system exhibit stable transgene expression.

プライマリーヒトT細胞のpiggyBacトランスポゾンシステムの変更

The piggyBac transposon system is naturally active, originally derived from the cabbage looper moth1,2. This non-viral system is plasmid based, most ...

Derivation of T Cells In Vitro from Mouse Embryonic Stem Cells

The OP9/OP9-DL1 co-culture system has become a well-established method for deriving differentiated blood cell types from embryonic and hematopoietic progenitors of both mouse and human origin. It is now used to address a growing variety of complex genetic, cellular and molecular questions related to hematopoiesis, and is at the cutting edge of efforts to translate these basic findings to therapeutic applications. The procedures are straightforward and routinely yield robust results. However, achieving successful hematopoietic differentiation in vitro requires special attention to the details of reagent and cell culture maintenance. Furthermore, the protocol features technique sensitive steps that, while not difficult, take care and practice to master. Here we focus on the procedures for differentiation of T lymphocytes from mouse embryonic stem cells (mESC). We provide a detailed protocol with discussions of the critical steps and parameters that enable reproducibly robust cellular differentiation in vitro. It is in the interest of the field to consider wider adoption of this technology, as it has the potential to reduce animal use, lower the cost and shorten the timelines of both basic and translational experimentation.

Derivation of T Cells In Vitro from Mouse Embryonic Stem Cells

Mouse embryonic stem cells can be differentiated to T cells in vitro using the OP9-DL1 co-culture system. Success in this procedure requires careful attention to reagent/cell maintenance, and key technique sensitive steps. Here we discuss these critical parameters and provide a detailed protocol to encourage adoption of this technology.

T細胞の導出<em&gt;体外</em&gt;マウス胚性幹細胞からの

The OP9/OP9-DL1 co-culture system has become a well-established method for deriving differentiated blood cell types from embryonic and hematopoietic ...

Generation of Human Alloantigen-specific T Cells from Peripheral Blood

The study of human T lymphocyte biology often involves examination of responses to activating ligands. T cells recognize and respond to processed peptide antigens presented by MHC (human ortholog HLA) molecules through the T cell receptor (TCR) in a highly sensitive and specific manner. While the primary function of T cells is to mediate protective immune responses to foreign antigens presented by self-MHC, T cells respond robustly to antigenic differences in allogeneic tissues. T cell responses to alloantigens can be described as either direct or indirect alloreactivity. In alloreactivity, the T cell responds through highly specific recognition of both the presented peptide and the MHC molecule. The robust oligoclonal response of T cells to allogeneic stimulation reflects the large number of potentially stimulatory alloantigens present in allogeneic tissues. While the breadth of alloreactive T cell responses is an important factor in initiating and mediating the pathology associated with biologically-relevant alloreactive responses such as graft versus host disease and allograft rejection, it can preclude analysis of T cell responses to allogeneic ligands. To this end, this protocol describes a method for generating alloreactive T cells from naive human peripheral blood leukocytes (PBL) that respond to known peptide-MHC (pMHC) alloantigens. The protocol applies pMHC multimer labeling, magnetic bead enrichment and flow cytometry to single cell in vitro culture methods for the generation of alloantigen-specific T cell clones. This enables studies of the biochemistry and function of T cells responding to allogeneic stimulation.

This article describes a method for the generation and propagation of human T cell clones that specifically respond to a defined alloantigen. This protocol can be adapted for cloning human T cells specific for a variety of peptide-MHC ligands.

末梢血からのヒトアロ抗原特異的T細胞の生成

The study of human T lymphocyte biology often involves examination of responses to activating ligands. T cells recognize and respond to processed peptide ...

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection occurring after allogeneic hematopoietic stem-cell transplantation. Viral-specific T cells from allogeneic donors, including third party donors, can be propagated ex vivo in compliance with current good manufacturing practice (cGMP), employing repeated rounds of antigen-driven stimulation to selectively propagate desired T cells. The identification and isolation of antigen-specific T cells can also be undertaken based upon the cytokine capture system of T cells that have been activated to secrete gamma-interferon (IFN-&#947;). However, widespread human application of the cytokine capture system (CCS) to help restore immunity has been limited as the production process is time-consuming and requires a skilled operator. The development of a second-generation cell enrichment device such as CliniMACS Prodigy now enables investigators to generate viral-specific T cells using an automated, less labor-intensive system. This device separates magnetically labeled cells from unlabeled cells using magnetic activated cell sorting technology to generate clinical-grade products, is engineered as a closed system and can be accessed and operated on the benchtop. We demonstrate the operation of this new automated cell enrichment device to manufacture CMV pp65-specific T cells obtained from a steady-state apheresis product obtained from a CMV seropositive donor. These isolated T cells can then be directly infused into a patient under institutional and federal regulatory supervision. All the bio-processing steps including removal of red blood cells, stimulation of T cells, separation of antigen-specific T cells, purification, and washing are fully automated. Devices such as this raise the possibility that T cells for human application can be manufactured outside of dedicated good manufacturing practice (GMP) facilities and instead be produced in blood banking facilities where staff can supervise automated protocols to produce multiple products.

The goal of this protocol is to manufacture pathogen-specific clinical-grade T cells using a bench-top, automated, second generation cell enrichment device that incorporates a closed cytokine capture system and does not require dedicated staff or use of a GMP facility. The cytomegalovirus pp65-specific-T cells generated can be directly administered to patients.

サイトカインキャプチャシステムを用いた臨床応用のためのサイトメガロウイルス特異的T細胞の自動化された細胞濃縮

The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection ...

T Cells Capture Bacteria by Transinfection from Dendritic Cells

Recently, we have shown, contrary to what is described, that CD4+ T cells, the paradigm of adaptive immune cells, capture bacteria from infected dendritic cells (DCs) by a process called transinfection. Here, we describe the analysis of the transinfection process, which occurs during the course of antigen presentation. This process was unveiled by using CD4+ T cells from transgenic OTII mice, which bear a T cell receptor (TCR) specific for a peptide of ovoalbumin (OVAp), which therefore can form stable immune complexes with infected dendritic cells loaded with this specific OVAp. The dynamics of green fluorescent protein (GFP)-expressing bacteria during DC-T cell transmission can be monitored by live-cell imaging and the quantification of bacterial transinfection can be performed by flow cytometry. In addition, transinfection can be quantified by a more sensitive method based in the use of gentamicin, a non-permeable aminoglycoside antibiotic killing extracellular bacteria but not intracellular ones. This classical method has been used previously in microbiology to study the efficiency of bacterial infections. We hereby explain the protocol of the complete process, from the isolation of the primary cells to the quantification of transinfection.

Here a protocol is presented to measure bacterial capture by CD4+ T cells which occurs during antigen presentation via transinfection from pre-infected dendritic cells (DC). We show how to perform the necessary steps: isolation of primary cells, infection of DC, DC/T cell conjugate formation, and measurement of bacterial T cell transfection.

T細胞は、樹状細胞からTransinfectionによって細菌をキャプチャ

Recently, we have shown, contrary to what is described, that CD4+ T cells, the paradigm of adaptive immune cells, capture bacteria from infected dendritic ...

Production of Human CRISPR-Engineered CAR-T Cells

Adoptive cell therapies using chimeric antigen receptor T cells (CAR-T cells) have demonstrated remarkable clinical efficacy in patients with hematological malignancies and are currently being investigated for various solid tumors. CAR-T cells are generated by removing T cells from a patient's blood and engineering them to express a synthetic immune receptor that redirects the T-cells to recognize and eliminate target tumor cells. Gene editing of CAR-T cells has the potential to improve safety of current CAR-T cell therapies and further increase the efficacy of CAR-T cells. Here, we describe methods for the activation, expansion, and characterization of human CRISPR-engineered CD19 directed CAR-T cells. This comprises transduction of the CAR lentiviral vector and use of single guide RNA (sgRNA) and Cas9 endonuclease to target genes of interest in T cells. The methods described in this protocol can be universally applied to other CAR constructs and target genes beyond the ones used for this study. Furthermore, this protocol discusses strategies for gRNA design, lead gRNA selection and target gene knockout validation to reproducibly achieve high-efficiency, multiplex CRISPR-Cas9 engineering of clinical grade human T cells.

Here, we present a protocol for gene editing in primary human T cells using CRISPR Cas Technology to modify CAR-T cells.

ヒトCRISPR設計CAR-T細胞の製造

Adoptive cell therapies using chimeric antigen receptor T cells (CAR-T cells) have demonstrated remarkable clinical efficacy in patients with ...

Adoptive Transfer of P14 T-Cells into Tumor-Bearing Mice

担がんマウスへのP14 T細胞の養子移植

マウス肺における抗原特異的T細胞の単離と特性評価

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers

The identification and characterization of antigen-specific T cells during health and disease remains a key to improving our understanding of immune pathophysiology. The technical challenges of tracking antigen-specific T cell populations within the endogenous T cell repertoire have been greatly advanced by the development of peptide:MHC tetramer reagents. These fluorescently labeled soluble multimers of MHC class I or class II molecules complexed to antigenic peptide epitopes bind directly to T cells with corresponding T cell receptor (TCR) specificity and can, therefore, identify antigen-specific T cell populations in their native state without a requirement for a functional response induced by ex vivo stimulation. For exceedingly rare populations, tetramer-bound T cells can be magnetically enriched to increase the sensitivity and reliability of detection.
As the investigation of tissue-resident T cell immunity deepens, there is a pressing need to identify antigen-specific T cells that traffic to and reside in nonlymphoid tissues. In this protocol, we present a detailed set of instructions for the isolation and characterization of antigen-specific T cells present within mouse lungs. This involves the isolation of T cells from digested lung tissue followed by a general T cell magnetic enrichment step and tetramer staining for flow cytometry analysis and sorting. The steps highlighted in this protocol utilize common techniques and readily available reagents, making it accessible for nearly any researcher engaged in mouse T cell immunology, and are highly adaptable for a variety of downstream analyses of any low frequency antigen-specific T cell population residing within the lungs.

著者スポットライト:Optimized Protocol for Detecting Antigen-Specific T cells in Mouse Lungs Using Tetramers(テトラマーを用いたマウス肺の抗原特異的T細胞検出のための最適化されたプロトコール)

We provide a detailed protocol for isolating and identifying rare antigen-specific T cell populations in mouse lungs through magnetic bead-based T cell enrichment and peptide:major histocompatibility complex (MHC) tetramers.

ペプチド:主要組織適合遺伝子複合体四量体を用いたマウス肺由来の希少抗原特異的T細胞の同定

The identification and characterization of antigen-specific T cells during health and disease remains a key to improving our understanding of immune ...